You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – The Japanese Ministry of Health, Labor, and Welfare has approved AstraZeneca's and MSD's olaparib (Lynparza) for molecularly defined subsets of patients with advanced ovarian, prostate, and pancreatic cancers.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.